Response to: 'Should patients starting biologics be screened for COVID-19?' by Cardenas-de la Garza et al
- PMID: 32699038
- DOI: 10.1136/annrheumdis-2020-218470
Response to: 'Should patients starting biologics be screened for COVID-19?' by Cardenas-de la Garza et al
Keywords: epidemiology; health services research; patient care team; quality indicators, health care.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.Ann Rheum Dis. 2020 Jul;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877. Epub 2020 Jun 5. Ann Rheum Dis. 2020. PMID: 32503854
-
Should patients starting biologics be screened for COVID-19?Ann Rheum Dis. 2022 Aug;81(8):e150. doi: 10.1136/annrheumdis-2020-218437. Epub 2020 Jul 6. Ann Rheum Dis. 2022. PMID: 32632031 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
